Group 1 - The company's revenue from its generic drug business decreased to 802 million yuan in 2024, a year-on-year decline of 21.18%, with a net profit attributable to shareholders of -53 million yuan, down 119.39% [1] - In Q1 2025, the company reported revenue of 129 million yuan, with a net profit attributable to shareholders of -26 million yuan [1] - Revenue breakdown for 2024 includes: preclinical pharmaceutical research income of 194 million yuan (-42.8%), clinical services income of 213 million yuan (+10.5%), self-developed results transformation income of 288 million yuan (-26.7%), equity sharing income of 8 million yuan (-71.3%), and commercial production income of 37 million yuan [1] Group 2 - As of the end of 2024, the company has nearly 300 self-developed projects that have been established but not yet transformed, with 91 projects completed in the small trial stage, 53 in the pilot scale-up stage, and 78 in the verification production stage [2] - The company has achieved 58 technology transformations of research results in 2024, with over 200 personnel in the new drug research and development team [2] - The company emphasizes its integrated drug development capabilities, combining pharmaceutical research, clinical trials, and customized R&D production, along with a comprehensive production service from intermediates to active pharmaceutical ingredients to formulations [2] Group 3 - The company forecasts revenues for 2025-2027 to be 704 million yuan, 778 million yuan, and 875 million yuan, representing year-on-year changes of -12.2%, +10.6%, and +12.4% respectively [3] - The net profit attributable to shareholders is projected to be 55 million yuan, 103 million yuan, and 119 million yuan for 2025-2027, with year-on-year growth rates of 204.4%, 87.9%, and 15.0% respectively [3] - The company anticipates short-term performance uncertainty due to policy impacts but expects to turn a profit by 2025, leading to a revised "accumulate" rating [3]

| 项目 | 内容 | | --- | --- | | 保荐机构名称 | 国金证券股份有限公司 | | 注册地址 | 成都市青羊区东城根上街 号 95 | | 法定代表人 | 冉云 | | 保荐代表人 | 余波、耿旭东 | | 联系电话 | 021-68826801 | 二、上市公司基本情况 国金证券股份有限公司 关于杭州百诚医药科技股份有限公司首次公开发行股票 并在创业板上市之持续督导保荐总结报告书 国金证券股份有限公司（以下简称"国金证券"或"保荐机构"）作为杭州 百诚医药科技股份有限公司（以下简称"百诚医药"、"公司"或"发行人"）首 次公开发行股票并在创业板上市的保荐机构，负责百诚医药上市后的持续督导工 作，持续督导期至 2024 年 12 月 31 日止。截至目前首次公开发行股票并在创业 板上市的持续督导期限己满，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》及《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等有关规定，保荐机构出具本保荐总结报告书。 一、保荐机构基本情况 | 项目 | 内容 | | --- | --- | | 上市公司名称 | 杭州百诚医药 ...

Core Viewpoint - The company Baicheng Pharmaceutical (301096.SZ) reported a significant decline in revenue and net profit for the year 2024 and the first quarter of 2025, indicating financial distress and operational challenges [2][3][4]. Financial Performance Summary - In 2024, the company achieved operating revenue of 802 million yuan, a decrease of 21.18% compared to 2023 [2][3]. - The net profit attributable to shareholders was -52.74 million yuan, a decline of 119.39% from the previous year's profit of 271.97 million yuan [2][3]. - The net profit after deducting non-recurring gains and losses was -72.63 million yuan, down 128.07% from 258.79 million yuan in 2023 [2][3]. - The net cash flow from operating activities was -195.86 million yuan, compared to a positive cash flow of 90.45 million yuan in the previous year, marking a 316.53% decrease [2][3]. Q1 2025 Performance Summary - For the first quarter of 2025, the company reported operating revenue of 129 million yuan, a decline of 40.32% year-on-year [4]. - The net profit attributable to shareholders was -26.20 million yuan, a decrease of 152.59% from the previous year's profit of 49.82 million yuan [4]. - The net profit after deducting non-recurring gains and losses was -36.18 million yuan, down 174.26% from 48.72 million yuan in the same period last year [4]. - The net cash flow from operating activities was -70.03 million yuan, an improvement of 42.59% compared to -121.98 million yuan in the previous year [4]. Stock Market Performance - Baicheng Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on December 20, 2021, with an initial price of 79.60 yuan per share [5]. - The stock reached a high of 120 yuan on its first trading day but has since experienced a downward trend, currently trading below its initial offering price [4][5]. Fundraising and Use of Proceeds - The company issued 27.04 million shares, raising a total of 2.153 billion yuan, with a net amount of 1.863 billion yuan after deducting issuance costs [5][6]. - The final net fundraising amount exceeded the original plan by 1.213 billion yuan, with the funds intended for the headquarters and R&D center project in Hangzhou [5].

Core Insights - The company reported significant declines in key financial metrics, including a net profit drop of 119.39% and a substantial decrease in cash flow from operating activities, raising market concerns [1][2][3][7]. Revenue and Profitability - The company's revenue for 2024 was 801,923,244.22 yuan, down 21.18% from 1,017,448,123.50 yuan in 2023, primarily due to the impact of policies on the generic drug business [2]. - The net profit attributable to shareholders was -52,742,809.58 yuan, compared to 271,966,149.52 yuan in 2023, marking a 119.39% decline [3]. - Basic earnings per share fell to -0.49 yuan from 2.51 yuan in 2023, a decrease of 119.52% [4]. Expenses and R&D Investment - Sales expenses increased by 55.01% to 14,961,617.19 yuan, while management expenses decreased by 39.77% to 77,469,868.54 yuan [5]. - R&D expenses rose by 32.06% to 318,288,767.42 yuan, indicating a commitment to innovation despite financial challenges [5][6]. Cash Flow Analysis - The net cash flow from operating activities plummeted by 316.53% to -195,856,925.64 yuan, reflecting difficulties in cash collection and increased salary payments [7]. - Investment activities resulted in a net cash outflow of -464,537,459.75 yuan, indicating aggressive asset investment despite short-term liquidity concerns [8]. - Financing activities saw a net cash inflow of 298,090,551.49 yuan, up 21.93%, primarily due to increased borrowing [9]. Risks and Challenges - The company faces multiple risks, including drug development failures, long R&D cycles, management challenges from scaling operations, and regulatory risks [10].

Core Viewpoint - The company is a comprehensive pharmaceutical research and development enterprise focused on technology development, providing various services including CRO, technology transfer, and CDMO to over 500 clients in the pharmaceutical industry [5][10]. Company Overview - The company specializes in contract research organization (CRO) services, technology transfer, and custom development and manufacturing organization (CDMO) services, catering to pharmaceutical companies and R&D investment firms [5][10]. - The company has provided over 800 pharmaceutical research and clinical trial services to more than 500 domestic clients [5]. Business Segments - **CRO Services**: The company offers a range of services including raw material synthesis, formulation research, quality research, and stability studies [6][8]. - **Clinical Trials**: The company assists in developing clinical trial protocols, monitoring trial processes, and managing data analysis [8]. - **Registration Services**: The company provides registration application services that comply with both domestic and international requirements, including ANDA and NDA submissions [9]. - **Technology Transfer**: The company engages in technology transfer for certain drug varieties, allowing clients to continue development based on initial results [10]. - **CDMO Services**: The CDMO business, primarily executed by a subsidiary, focuses on process development, optimization, and custom production for generic and innovative drugs [11]. - **Innovative Drug Development**: The company is committed to developing revolutionary drugs targeting major diseases, utilizing AI-driven platforms for drug discovery [12][13]. - **Contracted Innovative Drug Development**: The company enhances its capabilities in contracted R&D and provides comprehensive support to clients throughout the drug development process [14]. Financial Data - The company does not require retrospective adjustments or restatements of previous financial data [15]. - There are no significant discrepancies between the reported financial indicators and previously disclosed quarterly or semi-annual reports [15]. Shareholder Information - The report includes details on ordinary and preferred shareholders, with no preferred shareholders reported during the period [16]. - The company does not have any arrangements for differential voting rights [16]. Important Matters - There are no applicable bond situations as of the report approval date [17].

国金证券股份有限公司 关于杭州百诚医药科技股份有限公司 中国证监会 2021 年 11 月 9 日核发了《关于同意杭州百诚医药科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2021〕3566 号），同意公司首次 公开发行股票的注册申请。国金证券股份有限公司（以下简称"国金证券"或"保 荐机构"）作为杭州百诚医药科技股份有限公司（以下简称"百诚医药"或"公 司"）首次公开发行股票并在创业板上市的保荐机构，对公司 2024 年度募集资金 存放与使用情况进行了核查，具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意杭州百诚医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2021〕3566 号），本公司由主承销商国 金证券股份有限公司采用公开发行方式，向社会公众公开发行人民币普通股（A 股）股票 27,041,667 股，发行价为每股人民币 79.60 元，共计募集资金 2,152,516,693.20 元，坐扣承销和保荐费用 261,877,503.98 元后的募集资金为 1,890,639,189.22 元，已由主承销商国金证 ...

杭州百诚医药科技股份有限公司全体股东： 我们接受委托，审计了杭州百诚医药科技股份有限公司（以下简称百诚医药） 2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权 益变动表，以及财务报表附注，并出具了审计报告。在此基础上，我们核查了后 附的百诚医药管理层编制的《2024 年度营业收入扣除情况表》（以下简称扣除 情况表）。 目 录 一、关于营业收入扣除情况的专项核查意见………………………第 1—2 页 二、2024 年度营业收入扣除情况表…………………………………第 3—5 页 关于营业收入扣除情况的专项核查意见 天健审〔2025〕6754 号 一、对报告使用者和使用目的的限定 本报告仅供百诚医药年度报告披露时使用，不得用作任何其他目的。我们同 意将本报告作为百诚医药年度报告的必备文件，随同其他文件一起报送并对外披 露。 为了更好地理解百诚医药 2024 年度营业收入扣除情况，扣除情况表应当与 已审的财务报表一并阅读。 二、管理层的责任 百诚医药管理层的责任是提供真实、合法、完整的相关资料，按照《 ...

目 录 | 一、审计报告……………………………………………………… 第 1—5 | | 页 | | --- | --- | --- | | 二、财务报表……………………………………………………… 第 6—13 | | 页 | | （一）合并资产负债表…………………………………………… | 第 | 6 页 | | （二）母公司资产负债表………………………………………… | 第 | 7 页 | | （三）合并利润表………………………………………………… | 第 | 8 页 | | （四）母公司利润表……………………………………………… | 第 | 9 页 | | （五）合并现金流量表……………………………………………第 | | 10 页 | | （六）母公司现金流量表…………………………………………第 | | 11 页 | | （七）合并所有者权益变动表……………………………………第 | | 12 页 | | （八）母公司所有者权益变动表…………………………………第 | | 13 页 | | | | 审 计 报 告 天健审〔2025〕6750 号 杭州百诚医药科技股份有限公司全体股东： 一、审计意见 我们审计了杭 ...

国金证券股份有限公司 | 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0次 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于防 | | | 止关联方占用公司资源的制度、募集资金管理制度、内控 | 是 | | 制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月一次 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4、公司治理督导情况 | | | （1）列席公司股东大会次数 | 本年度内未列席 | | （2）列席公司董事会次数 | 本年度内未列席 | | （3）列席公司监事会次数 | 本年度内未列席 | | 5、现场检查情况 | | | （1）现场检查次数 | 1次 | | （2）现场检查报告是否按照本所规定报送 | 是 | | （3）现场检查发现的主要问题 ...

目 录 一、内部控制审计报告…………………………………………第 1—2 页 内部控制审计报告 天健审〔2025〕6751 号 杭州百诚医药科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了杭州百诚医药科技股份有限公司（以下简称百诚医药）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是百诚 医药公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，百诚医药公司于 2024 年 12 月 31 日按照《企业内部 ...